Skip to main content


Liver Cancer

Featured

Quiz
True or False: Compared with selective internal radiotherapy, sorafenib is a cost-effective treatment for hepatocellular carcinoma in the United States.
Guideline Updates
NCCN released an update to its guideline for hepatobiliary cancers, featuring updates in HCC, gallbladder cancer,…
Quiz
True or False: Pembrolizumab is not considered a cost-effective second-line therapy for treating HCC.
News
Compared with selective internal radiotherapy, sorafenib is not unlikely cost-effective for HCC in the United States.
News
Study findings suggest pembrolizumab is not a cost-effective second-line therapy for HCC at its current price in the US.
Back to Top